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 ABSTRACT 
 Quercetin has been shown to be a potent antioxidant, 
acts hepatoprotectively, and affects glucose and lipid 
metabolism in monogastrics. If this is also true in ru-
minants, quercetin could be beneficial in periparturient 
high-yielding dairy cows by ameliorating the negative 
effects of free radical formation and reducing the sever-
ity of liver lipidosis and ketosis. In a first attempt to 
evaluate effects of a long-term quercetin treatment, we 
intraduodenally administered twice daily 18 mg of quer-
cetin (Q)/kg of body weight to 5 late-lactation (215 d in 
milk) dairy cows over a period of 28 d. Frequent blood 
samples were taken before and during administration 
to determine plasma concentrations of flavonols and 
metabolites. Before and after 1 and 4 wk of Q admin-
istration, glycogen and fat content as well as mRNA 
expression of selected genes were measured in liver bi-
opsies. Furthermore, euglycemic, hyperinsulinemic, and 
hyperglycemic clamp studies were conducted before 
and after 2 wk of Q administration. During the experi-
ment, dry matter intake and most other zootechnical 
data remained unchanged. Milk protein content was 
increased in wk 2 and 4 of Q administration compared 
with basal values, whereas fat and lactose contents of 
milk remained unchanged. Plasma nonesterified fatty 
acids, γ-glutamyl transferase, cholesterol, glutamate 
dehydrogenase, triglyceride, and albumin concentra-
tions, as well as liver fat and glycogen concentrations, 
were not affected by Q supplementation. Plasma glu-
cose and β-hydroxybutyrate concentrations in plasma 
decreased and increased, respectively, under the influ-
ence of quercetin. During hyperglycemic clamp condi-
tions, the relative increase of plasma insulin was higher 
after 2 wk of Q administration, and a tendency for an 
increased rQUICKI (revised quantitative insulin sensi-
tivity check index) was observed. The relative mRNA 
expression levels of selected genes related to glucose 
metabolism, fat metabolism, and antioxidative status 
were not altered after 1 or 4 wk of Q supplementation. 
In conclusion, the effects on insulin release and sensitiv-
ity support the assumption that administration of Q 
could have positive effects on the metabolic adaption 
of high-yielding cows to early lactation. The increase of 
milk protein content in response to Q supplementation 
needs to be verified. 
 Key words:   duodenal cannula ,  quercetin ,  glucose 
production ,  antioxidative status 
 INTRODUCTION 
 The interest in naturally occurring plant constitu-
ents, such as flavonoids, that have potential health 
benefits for humans and animals has been increasing in 
recent years (Rochfort et al., 2008; Wallace et al., 2010; 
Egert and Rimbach, 2011; Galleano et al., 2012). The 
flavonoid quercetin, which belongs to the subgroup of 
flavonols, is one of the most potent antioxidants of plant 
origin. It has been shown to act hepatoprotectively but 
also affects glucose and lipid metabolism in vitro and 
in vivo in monogastric species (Kiso et al., 1984; Bravo, 
1998; Gasparin et al., 2003; Vessal et al., 2003; Shetty et 
al., 2004; Johnston et al., 2005; Kobayashi et al., 2010). 
In addition, quercetin affects several developmentally 
regulated genes (Wagh et al., 2012). The mechanisms 
underlying the effects of quercetin are not fully under-
stood but could be partly explained by the ability of 
quercetin to alter gene expression through epigenetic 
regulation such as DNA methylation, histone acetyla-
tion, and microRNA expression (Lee et al., 2005; Ruiz 
et al., 2007; Joven et al., 2012; Milenkovic et al., 2012). 
This should be true, in principal, for ruminants, given 
,QIOXHQFHRIZHHNLQWUDGXRGHQDOVXSSOHPHQWDWLRQRITXHUFHWLQ
RQSHUIRUPDQFHJOXFRVHPHWDEROLVPDQGP51$DEXQGDQFHRIJHQHV
UHODWHGWRJOXFRVHPHWDEROLVPDQGDQWLR[LGDWLYHVWDWXVLQGDLU\FRZV
$*RKONH&-,QJHOPDQQ*1UQEHUJ-0:HLW]HOÁ+0+DPPRQ6*|UV$6WDUNH1  
6:ROIIUDPDQG&&0HWJHV2
 * Institute of Nutritional Physiology “Oskar Kellner,” 
 † Institute of Genetics and Biometry, and 
 ‡ Institute of Reproductive Biology, Leibniz Institute for Farm Animal Biology (FBN), 18196 Dummerstorf, Germany 
 § Clinic for Cattle, School of Veterinary Medicine Hannover, 30173 Hannover, Germany 
 # Institute of Animal Nutrition and Physiology, Christian-Albrechts-University of Kiel, 24118 Kiel, Germany 
 
  
 Received March 25, 2013.
 Accepted August 4, 2013.
 1  Current address: Clinic for Ruminants and Swine, Faculty of 
Veterinary Medicine, University of Leipzig, 04103 Leipzig, Germany. 
 2 Corresponding author:  metges@fbn-dummerstorf.de 
Open access under CC BY-NC-ND license.
Journal of Dairy Science Vol. 96 No. 11, 2013
CHRONIC QUERCETIN SUPPLEMENTATION IN DAIRY COWS 6987
that flavonols are present in the circulation at sufficient 
concentration. Metabolic stress around calving associ-
ated with high milk yield in dairy cows leads to in-
creased production of free radicals and reactive oxygen 
species, which is related to clinically relevant patho-
logical conditions (Miller et al., 1993; Kankofer, 2002; 
Bertoni et al., 2008). Furthermore, adjustments of lipid 
and glucose metabolism are involved in the adaptation 
to energy deficiency during the periparturient period 
in dairy cows (Drackley et al., 2001; Hammon et al., 
2009). In this context, quercetin might be of relevance 
for early lactation cows because of its potential to al-
leviate excessive free radical formation and postcalving 
liver lipidosis and ketosis.
Our group has recently shown that quercetin aglycone 
is largely degraded in the rumen, and rutin, the rham-
noglucoside of quercetin, might be a rumen-protected 
form of quercetin (Berger et al., 2012). To circumvent 
ruminal degradation, we administered quercetin to 
the duodenum and demonstrated the acute bioavail-
ability of quercetin aglycone in dairy cows (Gohlke et 
al., 2013). On the basis of these findings, we explored 
effects of chronic duodenal administration of quercetin 
over 4 wk on performance, plasma metabolites, glucose 
metabolism, and hepatic gene expression related to the 
cows’ glucose metabolism and antioxidative status. To 
investigate chronic effects under physiological nonchal-
lenging conditions, the experiment was performed in 
nonpregnant, late-lactation dairy cows.
MATERIALS AND METHODS
Animals, Diets, and Measurement  
of Zootechnical Data
The study was conducted in compliance with the 
German Animal Protection regulations with approval 
of the authorities of the state Mecklenburg-Vorpom-
mern, Germany (Landesamt für Landwirtschaft, Leb-
ensmittelsicherheit und Fischereiwesen Mecklenburg-
Vorpommern, Germany; LALLF M-V/TSD/7221.3–
1.1–063/10).
For the experiment, 5 duodenally fistulated Holstein 
cows (>10,000 kg of milk in first lactation) in their 
second lactation with an average BW of 676.6 ± 6.1 kg 
were used. Surgical implantation of the duodenal can-
nulas was performed as described previously (Gohlke et 
al., 2013). At the start of the experiment, cows were in 
lactation wk 29, were nonpregnant, and had an average 
milk yield of 30.9 ± 1.7 kg/d. During the experimental 
period, the cows were kept in tiestalls on straw bed-
ding, received a TMR that was fed ad libitum, and had 
free access to water. Dietary composition and contents 
of ME and NEL were calculated according to the Ger-
man Society of Nutrition Physiology (GfE, 2001, 2009). 
Nutrient intake was targeted to meet recommenda-
tions of the German Society of Nutritional Physiology 
(GfE, 2001) for lactating cows. Dry matter content 
was determined weekly for grass silage, corn silage, 
and the TMR. Dry matter, CP, crude fat, and crude 
fiber in feed samples were determined according to the 
Weender standard procedure (Naumann and Bassler, 
1993). Feed components and chemical composition of 
the TMR are shown in Table 1. Cows were milked twice 
daily at 0400 and 1430 h.
To explore chronic effects of quercetin, we adminis-
tered 18 mg of quercetin equivalents (QE) per kg of 
BW in form of quercetin dihydrate (Carl Roth GmbH, 
Karlsruhe, Germany) twice daily (0800 and 1600 h) 
directly into the duodenum over a period of 28 d (Fig-
ure 1). This amounted to a total of 36 mg/kg of BW 
and day and was 16% more per day than the largest 
single bolus dose we used in the bioavailability stud-
ies (Gohlke et al., 2013). Milk yield, DMI, and body 
temperature were monitored daily, whereas BW, back 
fat thickness (Schröder and Staufenbiel, 2006), cir-
cumference of breast (measured directly behind the 
front legs) and abdomen (measured at the point of its 
largest width) and milk composition (% of milk fat, 
protein, and lactose) of the cows were measured weekly 
Table 1. Ingredients and chemical composition of the diet 
Item Amount
Ingredient (g/kg of DM)  
 Grass silage 179.6
 Corn silage 343.6
 Barley straw 25.6
 Grass hay 33.3
 Molassed sugar beet pulp1 79.8
 Canola meal extract 46.2
 Concentrate2 282.0
 Minerals3 9.9
Chemical composition4  
 DM (%) 42.51 ± 0.29
 CP 16.78 ± 0.22
 Crude fat 2.81 ± 0.00
 Crude fiber 14.88 ± 0.03
 NDF 30.54 ± 0.08
 ADF 16.69 ± 0.04
 ME (MJ/kg of DM) 11.45 ± 0.01
 NEL (MJ/kg of DM) 6.91 ± 0.00
1Arp, Thordsen, Rautenberg GmbH & Co KG (Sollerupmühle, 
Germany): 7.3 MJ of NEL/kg of DM, 153 g of utilizable protein/kg 
of DM.
2Concentrate MF 2000 (Vollkraft Mischfutterwerke GmbH, Güstrow, 
Germany): 33% extracted soy meal, 20% corn, 17% wheat gluten, 8% 
extracted rapeseed meal, 5% sugar beet pulp, 2% sodium hydrogen 
carbonate, 1.3% calcium carbonate, 0.2% sodium chloride, 8.0 MJ of 
NEL/kg DM, 204 g of utilizable protein/kg DM.
3Rinderstolz 9522 lactation (Salvana Tiernahrung GmbH, Sparrieshoop, 
Germany): 92% crude ash, 20% calcium, 5% phosphorus, 6% magne-
sium, 8% sodium.
4Values in % of DM unless otherwise specified.
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before and during the supplementation period. Energy-
corrected milk was calculated as ECM = [(0.38 × g of 
crude fat + 0.024 × g of CP + 0.017 × g of lactose) × 
kg of milk]/3.14 (Reist et al., 2003).
Blood Sampling and Analysis
Blood samples to measure plasma flavonol concentra-
tions (Li-Heparinate monovettes; Sarstedt, Nümbrecht, 
Germany) were collected at 1200 h once before and on 
every Monday and Friday during the quercetin supple-
mentation period. In addition, each Monday morning 
before the first quercetin dose of the day, another blood 
sample was taken (Figure 1). All blood samples were 
centrifuged at 1,500 × g for 20 min at 4°C, and plas-
ma aliquots were stored at −80°C until analysis. For 
measurement of plasma metabolites [glucose, NEFA, 
γ-glutamyl transferase (GGT), BHBA, cholesterol, 
glutamate dehydrogenase (GLDH), triglycerides, and 
albumin), blood samples in K-EDTA monovettes 
(Sarstedt) were collected before and 3 times a week 
during the supplementation period (Figure 1). Plasma 
concentrations of quercetin aglycone and its methyl-
ated (isorhamnetin and tamarixetin) and dehydroxyl-
ated (kaempferol) derivatives were analyzed by HPLC 
with fluorescence detection as described previously 
(Gohlke et al., 2013). The detection limit of flavonol 
was ≤10 nmol/L and the recovery rate of flavonols was 
92 ± 2% (mean ± SEM). Inter- and intraassay coef-
ficients of variability for quercetin were 7.2 and 0.5%, 
respectively. The sum of quercetin and its metabolites 
in plasma is referred to as total flavonols.
Glucose, NEFA, GGT, BHBA, cholesterol, GLDH, 
triglyceride, and albumin concentrations in plasma 
were analyzed by the clinic for cattle of the Stiftung 
Tierärztliche Hochschule Hannover, Germany, using an 
automatic analyzer (ABX Pentra 400, Horiba Medical, 
Montpellier, France) and commercial kits (glucose/cho-
lesterol: kit no. 553-230/553-124, MTI Diagnostics, Id-
stein, Germany; NEFA: kit no. 600-215S, Wako Chemi-
cals GmbH, Neuss, Germany; BHBA: kit no. RB 1008, 
Randox Laboratories Ltd., Crumlin, United Kingdom; 
GGT: kit no. 10242103, Hitado Diagnostic Systems, 
Möhnesee, Germany; GLDH: kit no. 11929992216, 
Roche Diagnostics GmbH, Mannheim, Germany; tri-
glycerides/albumin: kit no. A11A01640/ A11A01664, 
ABX-Horiba Medical).
Clamp Studies
To explore insulin sensitivity and pancreatic insulin 
secretion, respectively, in response to quercetin, eug-
lycemic, hyperinsulinemic (EHC), and hyperglycemic 
(HGC) clamp studies were conducted before and in 
wk 3 of quercetin supplementation (Figure 1). Between 
the EHC and HGC studies, an idle period of at least 1 
d was maintained. Before the clamp studies were con-
ducted, indwelling catheters (Certofix mono, B. Braun 
Melsungen AG, Melsungen, Germany) were implanted 
into both jugular veins of the cows.
After 7 h of feed withdrawal, EHC studies began at 
1000 h (t = 0 min), with the start of the infusion of 
bovine insulin at a rate of 6 U/kg per minute and lasted 
for 6 h (Blum et al., 1999). The insulin infusion solution 
for the EHC was prepared individually for each cow by 
dissolving purified bovine insulin (Hybri-Max, Sigma-
Aldrich Chemie GmbH, Steinheim, Germany; activity 
31 U/mg) in 460 mL of a solution consisting of 0.9% 
NaCl, 0.1% BSA, 2.4% KCl, and 4% plasma of the 
same cow in double distilled water. Glucose infusion 
commenced 5 min after the insulin infusion at a rate of 
4 mL/min of 40% (wt/vol) glucose solution (B. Braun 
Figure 1. Schematic representation of the experimental procedures. LB = liver biopsy, EHC = euglycemic, hyperinsulinemic clamp study 
+ [13C6] glucose tracer study (insert); HGC = hyperglycemic clamp study. Double arrows indicate blood samples taken at 0800 and 1200 h; 
single arrows indicate blood samples taken at 1200 h; dashed arrows indicate blood samples taken during tracer studies for determination of 
endogenous glucose production (eGP), glucose rate of appearance (GlucRaEHC), and glucose oxidation (GOx).
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Melsungen AG). During the clamp study, plasma was 
sampled every 5 min and immediately analyzed for glu-
cose concentration (1500 Sport YSI Lactate analyzer, 
Kreienbaum, Langenfeld, Germany). Glucose infusion 
rate (GIR) was adjusted every 5 min to maintain the 
basal plasma glucose concentration (mean glucose con-
centration of 3 samples taken at 40, 30, and 20 min 
before the start of the insulin infusions ± 5%). Before 
and every 30 min after the start of the insulin infu-
sion, blood samples in K-EDTA monovettes (Sarstedt) 
were taken, centrifuged at 1,500 × g for 20 min at 4°C, 
and stored at −20°C for subsequent determination of 
the plasma insulin concentration with a commercially 
available RIA (Porcine Insulin RIA Kit, Millipore, Bil-
lerica, MA).
The HGC study was conducted 2 d after the EHC 
study. After a 5-h feed withdrawal, 3 basal plasma 
samples were collected at intervals of 7 min to deter-
mine basal glucose and insulin concentrations. The aim 
of the HGC study was to increase plasma glucose con-
centrations 50% ± 5% above the basal level. At 0830 h, 
glucose infusion started at a rate of 4 mL/min of 40% 
(wt/vol) glucose solution (B. Braun Melsungen AG) 
and lasted for 4 h, during which the GIR was adjusted 
every 5 min if necessary to maintain hyperglycemia. 
Over the clamp period, blood was sampled and handled 
as described for the EHC.
For evaluation of the clamp studies the following 
variables were calculated. Basal glucose and insulin 
concentrations in plasma (bGC and bIC) were deter-
mined as arithmetic means of the glucose and insulin 
concentrations of the 3 (EHC) or 2 (HGC) basal samples 
taken before the start of the clamp study. The steady-
state glucose and insulin concentrations (ssGC and 
ssIC) in plasma were calculated as arithmetic means 
of plasma concentrations during the last 2 h (EHC) or 
1.5 h (HGC) of the clamp studies. The steady-state glu-
cose infusion rate (ssGIR) was computed as arithmetic 
mean of the glucose infusion rate during the same time 
periods used for calculation of ssGC and ssIC. The in-
sulin sensitivity index (ISI) was calculated as the ratio 
of ssGIR (μmol/kg of BW per minute) to ssIC (μU/
mL) according to Mitrakou et al. (1992), expressing 
the amount of glucose utilized per unit of insulin. The 
quantitative insulin sensitivity check index (QUICKI; 
Katz et al., 2000) and the revised QUICKI (rQUICKI; 
Perseghin et al., 2001; Holtenius and Holtenius, 2007) 
were assessed using the following equations:
QUICKI = 1/[log bGC (mg/dL) + log bIC (μU/mL)]
rQUICKI = 1/ [log bGC (mg/dL) + log bIC  
(μU/mL) + log bNEFA (mmol/L)],
where bNEFA = basal concentration of NEFA in 
plasma. Furthermore, for analysis of HGC studies, the 
absolute and relative increase of insulin plasma levels 
(IIabs and IIrel) was calculated according to IIabs = ssIC 
– bIC, and IIrel = ssIC/bIC.
Tracer Studies
Before and during the EHC studies, the glucose rate 
of appearance in plasma (GlucRa) was determined us-
ing a primed, continuous intravenous [13C6] glucose (99 
atom %, Euriso-Top GmbH, Saarbrücken, Germany) 
infusion before the start of and 6 h into the clamp study 
(Figure 1). Tracer glucose infusion started at 0700 h (t 
= −180 min relative to start of the EHC study) with 
a bolus injection of 5.38 μmol of [13C6] glucose/kg of 
BW followed immediately by a constant infusion (7.53 
μmol of [13C6] glucose/kg of BW
 per hour) for 9 h (from 
−180 to 360 min). Blood was collected at −190, −185, 
−90, −60, −30, 0, 60, 120, 180, 210, 240, 270, 300, 330, 
and 360 min relative to the start of the EHC study in 
Li-heparinized monovettes for measurements of [13C6] 
glucose enrichment to assess GlucRa, and in full-blood 
K-EDTA tubes (Sarstedt) for determination of 13CO2 
enrichment to calculate glucose oxidation rate.
Plasma enrichment of [13C6] glucose was determined 
by converting glucose to its aldonitrile pentaacetate de-
rivative as previously described (Junghans et al., 2010). 
The [13C6] glucose enrichment was analyzed by GC-MS 
(QP 2010, GC 2010, Shimadzu Deutschland GmbH, 
Duisburg, Germany) using positive chemical ionization 
and m/z 334 and 328 as the diagnostic ion fragments to 
calculate m + 6/m + 0 (Junghans et al., 2010).
For determination of 13C in blood CO2, 1 mL of lactic 
acid (10% wt/wt) was added to 1 mL of whole blood 
in 10-mL screw-cap glass tubes (Exetainer, Labco Ltd., 
Buckinghamshire, UK), previously flushed with argon. 
Samples were incubated for at least 2 h at room tem-
perature. Using gas isotope ratio mass spectrometry 
(Delta Plus XL, Thermo Fischer Scientific GmbH, 
Dreieich, Germany) coupled with the Gas Bench II 
(Thermo Fisher Scientific GmbH) the 13C:12C isotopic 
ratio of the released blood CO2 was measured in the 
headspace. Enrichments are expressed as 13C atom % 
excess.
The GlucRa derived from intravenous [13C6] glucose 
infusion was calculated as GlucRa = IIV × [(IEinf/IEIV) 
− 1], where IIV is the intravenous infusion rate of [
13C6] 
glucose [μmol/kg of BW per hour], IEinf is the isotopic 
enrichment (mole percent excess) of [13C6] glucose in 
the tracer infusion, and IEIV is the isotopic enrichment 
(mol ratio excess) of [13C6] glucose in plasma over base-
line at isotopic steady state (absence of a significant 
slope). The GlucRa was calculated during basal condi-
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tions before the start of the EHC study (−90 – 0 min) 
for determination of endogenous glucose production 
rate (eGP) and during EHC conditions (180 – 360 
min, GlucRaEHC; Figure 1). In addition, GlucRaEHC 
was corrected for the infusion of unlabeled glucose dur-
ing the EHC according to cGlucRaEHC = GlucRaEHC 
− ICLAMP, where ICLAMP is exogenous glucose infusion 
(mmol/kg of BW per hour).
Glucose oxidation rate (GOx; mmol/kg of BW per 
hour) was calculated before and during the clamp 
study according to GOx = CO2Ra × IECO2 × (6 × 
IEIV)
−1 (Kien, 1989), where IECO2 (atom % excess) is 
the steady-state 13C enrichment of CO2 derived from 
oxidized glucose in blood before (−60 to 0 min rela-
tive to the clamp start) and during EHC (210 to 360 
min after the clamp start), and IEIV (mole % excess) is 
the steady-state isotopic enrichment of [13C6] glucose in 
plasma. The CO2 rate of appearance (CO2Ra; mmol/
kg of BW per hour) was calculated based on the CO2 
production (VCO2 in L/kg of BW per day) of lactating 
Holstein cows previously measured by indirect calorim-
etry [S. Börner, M. Derno, and B. Kuhla, Leibniz In-
stitute for Farm Animal Biology (FBN), Dummerstorf, 
Germany, unpublished] as follows: CO2Ra = VCO2 × 
(22.4 × RF[13C])−1, where 22.4 is the amount (L) in 1 
mol of CO2 and including appropriate corrections to 
convert to mmol/kg of BW per hour. The recovery fac-
tor (RF) 0.7 was used to correct for the incomplete 13C 
recovery in breath from the rate of CO2 appearance in 
blood (Junghans et al., 2007).
Liver Sampling and Analysis
Before, after 1 wk of, and on the last day of quercetin 
supplementation (d 28) liver biopsies were aseptically 
taken (Figure 1) under ultrasonographic control at the 
10th or 11th intercostal space after local anesthesia 
(procaine hydrochloride 20 mg/mL and epinephrine 
0.025 mg/mL, Selectavet, Weyarn/Holzolling, Germa-
ny) using a custom-made biopsy needle (6 mm outside 
diameter). Biopsied tissue samples were immediately 
frozen in liquid nitrogen and then stored at −80°C until 
further analysis. Before analysis, all liver samples were 
ground in liquid nitrogen.
Using a commercial photometric test kit based on 
amyloglucosidase, catalyzed release of glucose (kit no. 
10207748035, Boehringer Mannheim, Mannheim, Ger-
many) liver glycogen content was determined. Based 
on carbon and nitrogen content of the liver samples, 
total liver fat content was measured as described 
(Kuhla et al., 2004). Liver fat content was calculated 
as follows:
Liver fat (% of DM) = 1.3038 × C (% of DM)  
– 4.237 × N (% of DM) – 0.58 × glycogen  
(% of DM) – 0.5215 × glucose (% of DM).
For determination of transcript abundance of selected 
genes related to glucose metabolism, lipid metabolism, 
and antioxidative status, total RNA was extracted from 
liver samples using Trizol (Invitrogen, Karlsruhe, Ger-
many). The integrity and purity of RNA was verified 
by measurement of optical density and by electropho-
resis using ethidium bromide staining. One microgram 
of extracted RNA was reverse transcribed into cDNA 
with 200 U of Moloney murine leukemia virus reverse 
transcriptase (Promega Corp., Madison, WI) using 100 
pmol of random primers (Invitrogen).
Real-time reverse transcription-PCR was performed 
using SYBR Green I as fluorescence dye (Light Cycler 
Fast start DNA MasterPlus SYBR Green I, Roche Di-
agnostics GmbH, Mannheim, Germany) by LightCycler 
(Roche Molecular Biochemicals, Mannheim, Germany). 
The primer sequences (Table 2) for PCR measurement 
of glucose-6-phosphatase (G6P; EC 3.1.3.9), phospho-
enolpyruvate carboxykinase (EC 4.1.1.32; cytosolic: 
PEPCK-C; mitochondrial: PEPCK-M), and py-
ruvate carboxylase (PC; EC 6.4.1.1) were according 
to Hammon et al. (2009). The primer for carnitine 
palmitoyltransferase 1A (CPT1A; EC 2.3.1.21) was 
as reported by van Dorland et al. (2009). For mea-
surement of mRNA expression level of superoxide 
dismutase (SOD-1; EC 1.15.1.1), catalase (CAT; 
EC 1.11.1.6), and glutathione peroxidase (GPx; EC 
1.11.1.12), primers previously used in bovine tissues 
were selected (Wrenzycki et al., 2000; Aitken et al., 
2009; Mundim et al., 2009). Products of these primers 
were verified by sequencing using ABI Sequencing kit 
(ABI Prism Big Dye Terminator Cycle, Life Technolo-
gies GmbH, Darmstadt, Germany) and an ABI 3130 
Genetic Analyzer (Life Technologies GmbH). Primer 
sequences, annealing temperatures, and product sizes 
are reported in Table 2.
Specific PCR products were demonstrated through 
a melting curve analysis program by the LightCycler 
(Roche Molecular Biochemicals) and all PCR products 
moved with one single band and showed the expected 
size upon agarose gel electrophoresis.
Quantification of mRNA was performed by rela-
tive expression using GAPDH, β-actin, and PGK-1 as 
reference genes. Crossing points, which represent the 
cycle (quantification cycle; Cq) at which fluorescence 
increases appreciably above background fluorescence, 
were determined for each enzyme and the 3 reference 
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genes for each cow (Rasmussen, 2001). The Cq values 
of all enzymes and reference genes were corrected for 
different runs by an internal standard for all transcripts 
(ΔCq). The mean ΔCq of the 3 reference genes (Ref) 
was used for normalization of the amount of each target 
gene in the respective sample, resulting in
ΔΔCq = ΔCqtarget − ΔCqRef.
The relative expression levels (R) of each enzyme were 
calculated according to Pfaffl (2001) as R = E−ΔΔCq, 
where we assumed an optimal efficiency of PCR (E 
= 2) for all target and reference genes (i.e., product 
is replicated every cycle). Based on the evaluation of 
crossing points, the expression of reference genes GAP-
DH, β-actin, and PGK-1 was not affected by quercetin 
administration or week of sampling.
Statistical Analysis
Variables measured daily were condensed per week 
but data from wk −1 and 3 were excluded from the 
statistical analysis because execution of clamp stud-
ies affected some of the measured variables. Data 
were evaluated with SAS/STAT 9.2 (SAS Institute 
Inc., Cary, NC) by using repeated-measures ANOVA 
(PROC MIXED) with cow as repeated subject and 
type = first-order autoregressive [AR(1)]. For analysis 
of the zootechnical data (milk yield, DMI, BW, back 
fat thickness, circumference of breast, circumference 
of abdomen, and fat, protein, and lactose contents in 
milk), and the results of the blood sample analyses (to-
tal flavonols, glucose, NEFA, GGT, BHBA, cholesterol, 
GLDH, triglyceride, and albumin) and liver biopsies 
(mRNA expression levels, glycogen and fat contents, 
and the ratio between fat and glycogen), the model 
included the repeated factor week of sampling (before 
or during quercetin administration). For evaluation of 
glucose and insulin concentrations in plasma, as well 
as the glucose infusion rate during the clamp studies, 
the model included the factors flavonoid supplementa-
tion (Flav; yes or no) and time during the clamp study 
and the interaction flavonoid × time. Insulin sensitivity 
indices calculated for EHC and HGC were analyzed 
using a one-factorial model with the factor flavonoid 
supplementation (yes or no). For analysis of eGP, Glu-
cRaEHC, GOxBasal and GOxEHC, the factors flavonoid, 
clamp study (yes or no), and the interaction flavonoid 
× clamp were used (see Figure 1). The model used for 
analysis of cGlucRaEHC included only the factor flavo-
noid supplementation (yes or no).
Effects were considered significant when P ≤ 0.05, 
and discussed as a trend if 0.05 < P ≤ 0.1. In all mod-
els, differences between treatments were detected using 
the Tukey-Kramer or the Dunnett test. Data are pre-
sented as least squares means (LSM) ± standard error 
of the mean (SEM).
RESULTS AND DISCUSSION
Quercetin has been shown to affect glucose me-
tabolism in monogastric species (Ammar and Al-Okbi, 
1988; Cermak et al., 2004; Shetty et al., 2004; Johnston 
et al., 2005). The observed decrease of plasma glucose 
under quercetin in our study (P < 0.05; Figure 2) is in 
accordance with quercetin effects described in rats. For 
example, injection of 10 mg of QE/kg of BW or supple-
mentation of the basal diet with 1 g of QE/kg decreased 
Table 2. Primers and conditions used for real-time reverse transcription-PCR analyses 
Gene1 Direction Primer sequence 5c→ 3c
Annealing 
temperature (°C)
Length 
(bp)
Gene Bank 
accession no.
G6P Forward ATGTTGTGGTTGGGATTCTGG 60 275 BC114011
Reverse CACCTTCGCTTGGCTTTCTC    
PC Forward ACACCAACTACCCCGACAATG 60 353 AY185595
Reverse CAGCGGGAGGTCAGGGAAG    
PEPCK-C Forward CTCAGCTGGCAGCACGGTGTG 60 578 AY145503
Reverse TGCTCCTGGTGCGTTGTATGG    
PEPCK-M Forward TATGAGGCCTTCAACTGGCGC 65 365 XM583200
Reverse AGATCCAAGGCGCCTTCCTTA    
SOD Forward AAGGCCGTGTGCGTGCTGAA 60 246 M81129
Reverse CAGGTCTCCAACATGCCTCT    
GPx Forward CTTCCCCTGCAACCAGTTTG 60 62 X13684
Reverse GGCAATTCAGGATCTCCTCGTT    
CAT Forward GTTCGCTTCTCCACTGTT 56 454 BC103066
Reverse GGCCATAGTCAGGATCTT    
CPT1A Forward CAAAACCATGTTGTACAGCTTCCA 54 111 BF039285
Reverse GCTTCCTTCATCAGAGGCTTCA    
1G6P = glucose-6-phosphatase; PC = pyruvate carboxylase; PEPCK-C = cytosolic phosphoenolpyruvate carboxykinase; PEPCK-M = mito-
chondrial phosphoenolpyruvate carboxykinase; SOD = superoxide dismutase; GPx = glutathione peroxidase; CAT = catalase; and CPT1A = 
carnitine palmitoyltransferase 1A.
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blood glucose levels in diabetic rats (Vessal et al., 2003; 
Shetty et al., 2004), an effect that was also observed by 
others using different quercetin dosages [50–200 mg/kg 
of BW or 0.04–0.08% (wt/wt) of diet; Ammar and Al-
Okbi, 1988; Kannappan and Anuradha, 2009; Kim et 
al., 2011; Jeong et al., 2012]. Concentrations of glucose 
in wk 3 of quercetin supplementation (clamp studies) 
did not differ from pre-supplementation values (data 
not shown), likely due to the infusion of glucose and 
insulin in the clamp studies (Figure 2). The plasma glu-
cose and insulin concentrations, as well as the glucose 
infusion rate measured during EHC clamp studies, were 
not altered by flavonoid administration (Figure 3), but 
we observed a tendency for altered plasma insulin con-
centrations (P = 0.06) under HGC conditions (Figure 
4). A more detailed examination showed that although 
basal insulin concentrations was not altered by querce-
tin supplementation in wk 3, the relative increase of in-
sulin (IIrel) was higher (P = 0.012; Tables 3 and 4). Fur-
ther, rQUICKI tended to be increased during quercetin 
supplementation (P = 0.06; Table 4). Also, under EHC 
conditions, ssIC and rQUICKI were numerically higher 
under quercetin (P = 0.11 and P = 0.14, respectively; 
Table 3). The values of eGP, GlucRaEHC, cGlucRaEHC, 
and GOx, whether basal or during EHC, were not af-
fected by quercetin administration (Table 5). Although 
quercetin supplementation has been shown to inhibit 
glucose uptake into intestinal cells (Cermak et al., 2004; 
Johnston et al., 2005; Manzano and Williamson, 2010), 
it was reported to enhance glucose uptake in muscle 
cells (Eid et al., 2010) and has been shown to reduce 
G6P activity in the rat liver in vitro (Estrada et al., 
2005). Moreover, it has been reported that rats (10 mg 
of QE/kg of BW over a period of 10 d) showed an 
increased number of pancreatic islets, and the addition 
of 10 and 100 μmol of QE/L to isolated pancreatic 
islets of rats enhanced insulin release (Hii and Howell, 
1985; Vessal et al., 2003). In contrast to monogastrics, 
in ruminants very little glucose originates from glucose 
absorption, therefore a potential impairment of glucose 
absorption from the intestine will have only minor 
consequences for plasma glucose concentrations (Bell 
and Bauman, 1997). Endogenous glucose production 
(i.e., gluconeogenesis and glycogenolysis) provides most 
of the glucose in ruminants. However, we could not 
find differences in eGP rates and GOx before and in 
the third week of chronic quercetin supplementation. 
Furthermore, the mRNA expression levels of G6P, PC, 
PEPCK-C, PEPCK-M, and CPT1A, enzymes involved 
in gluconeogenesis and fat metabolism, were not altered 
in the liver of cows after 1 or 4 wk of quercetin treat-
ment (Table 6), and the fat and glycogen concentration 
of the liver as well as the ratio of liver fat and gly-
cogen were not affected by quercetin supplementation 
(P > 0.7; Figure 5). Thus, we suggest that a faster 
release of insulin together with a facilitated uptake of 
glucose in muscle and perhaps other tissues might be 
responsible for the lower levels of glucose measured in 
plasma of our cows. This conclusion is supported by the 
increased relative insulin release observed in the HGC 
study and the fact that cows tended to show higher 
insulin sensitivity in wk 3 of quercetin administration 
(Table 4). Nevertheless, GOx was about 2 times higher 
in the late-lactation cows in this study compared with 
in early-lactation cows and GOx amounted to approxi-
mately 30% of glucose production, whereas it was only 
10% in early lactation, as reported recently (Hötger 
et al., 2013). Interestingly, cGlucRaEHC values showed 
that glucose production was not completely suppressed 
in spite of ample glucose and insulin infusion during 
EHC studies. The observed quercetin-related changes 
in plasma glucose levels, insulin release, and insulin 
sensitivity are in line with the suggestion that quercetin 
intake could benefit the treatment and prevention of 
type 2 diabetes in humans (Aguirre et al., 2011).
Milk yield was lower at the end of the supplementa-
tion period than in wk 2 (P = 0.017), but was not 
Figure 2. Plasma concentrations of glucose before (210 DIM) and 
during quercetin administration (215–240 DIM) at 1200 h. Values are 
LSM ± SEM of 5 cows. Different symbols represent values of indi-
vidual cows. *Significantly different from baseline value (P ≤ 0.05). 
CLAMP area indicates days on which clamp studies were performed 
in the cows (see Materials and Methods).
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changed compared with wk −2 (P > 0.3; Table 7). The 
lower milk yield and higher BW observed in wk 4 of 
quercetin supplementation were likely due to physiolog-
ical changes associated with the lactation stage of the 
cows rather than due to changes caused by the querce-
tin administration. We have previously reported that 
an acute dose of quercetin did not change milk yield 
(Gohlke et al., 2013). However, in the present study, 
chronic quercetin administration increased the protein 
content of milk during the whole supplementation pe-
riod, whereas fat and lactose contents in milk remained 
unchanged (Table 7). Based on results of in vitro stud-
ies, Leiber et al. (2012) suggested that rutin (50 g/kg 
of ryegrass silage), the rhamnoglucoside of quercetin, 
partly protects dietary protein from ruminal degrada-
tion, which would increase the amount of amino acids 
available for absorption in the small intestine. There-
fore, the protein supply of the cows would be enhanced, 
which could result in an increase of protein content 
in milk. Whether quercetin administered to the small 
intestine could possibly increase amino acid availability 
for the cow is unknown; however, we speculate that 
one possible mechanism is that quercetin might reduce 
amino acid oxidation during the first pass by altering 
the microbial population in the intestine. Another ex-
planation of the increase in milk protein relates to find-
ings of Griinari et al. (1997). They reported a modest 
increase in milk protein during 4-d EHC studies with 
Figure 3. Concentration profiles of plasma glucose and insulin, as well as glucose infusion rate (GIR) during euglycemic, hyperinsulinemic 
clamp studies conducted before quercetin administration (basal) and in wk 3 of quercetin supplementation. Values are LSM ± SEM of 5 cows. 
P-values for the main factors flavonoid supplementation (yes or no; Flav), time during the clamp study (Time), and interaction are shown for 
the individual variables. For details of timing, see Figure 1.
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increasing plasma insulin concentrations. Thus, the 
observed effects of quercetin on milk protein concentra-
tion might be related to plasma insulin concentration 
via the insulin-like-growth (IGF) system (McGuire et 
al., 1995). We did not measure IGF-I and respective 
binding proteins in the plasma in the current study, but 
given the economic importance of the protein content 
of milk, the finding of an increased milk protein concen-
tration must be confirmed and the mechanisms of this 
quercetin effect examined in future studies. Feed intake 
(DMI) and all other zootechnical data (circumference 
of breast and abdomen, back fat thickness, and ECM) 
were unchanged during the experiment (Table 7).
During quercetin supplementation, plasma BHBA 
was slightly but significantly higher (P < 0.05; Figure 
6), but DMI and feed composition remained unchanged 
during the experimental period, plasma values of NEFA 
and triglycerides remained unchanged, and the BW of 
cows increased. Thus, energy deficiency or an increase 
of ketogenesis or increased production of BHBA in 
the rumen wall due to increased butyrate production 
(Duske et al., 2009) can be excluded and the mobi-
lization of body fat as a source of BHBA is unlikely. 
Although the reasons for the observed higher BHBA 
plasma concentrations remain unclear, the higher 
BHBA levels remain within the physiological range and 
Figure 4. Concentration profiles of plasma glucose and insulin, as well as glucose infusion rate (GIR) during hyperglycemic clamp studies 
conducted before quercetin administration (basal) and in wk 3 of quercetin supplementation. Values are LSM ± SEM of 5 cows. P-values for 
the main factors flavonoid supplementation (yes or no; Flav), time during the clamp study (Time), and interaction are shown for the individual 
variables. For details of timing, see Figure 1. 
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do not indicate a potential metabolic problem in the 
experimental cows. Plasma concentrations of NEFA, 
GGT, cholesterol, GLDH, triglycerides, and albumin 
were not affected by quercetin supplementation and 
did not change with respect to values measured before 
quercetin supplementation (data not shown).
Quercetin is known to be a potent antioxidant and 
has been shown to influence enzymes involved in scav-
enging reactive oxygen species in in vitro and in vivo 
experiments (Igarashi and Ohmuma, 1995; Molina et 
al., 2003; Röhrdanz et al., 2003; Sancheti et al., 2011; 
Vieira et al., 2011; Jeong et al., 2012). We measured 
the transcript abundances of enzymes involved in free 
radical defense. However, we could not find differences 
in the expression of SOD, CAT, or GPx after 1 or 4 wk 
of quercetin supplementation (Table 6). Several factors 
could explain this. First, administration of quercetin at 
a dose of 18 mg of QE/kg of BW twice a day resulted 
in higher concentrations of total flavonols in plasma 
samples taken at 1200 h compared with basal values 
(P < 0.05; Figure 7), but the total flavonol content of 
plasma samples taken at 0800 h (i.e., 16 h after the last 
quercetin dose of the previous day) immediately before 
quercetin administration was in the range of the basal 
concentrations (P > 0.2). This agrees with our previ-
ous observations in dairy cows that plasma baseline 
concentrations of total flavonols were reached again 4 h 
after an acute intraduodenal dose of quercetin (Gohlke 
Table 3. Insulin sensitivity indices determined during euglycemic, hyperinsulinemic clamp studies before (wk 
−1) and in wk 3 of quercetin supplementation1 
Item2
Week
SEM P-value−1 3
bGC (mmol/L) 4.16 4.27 0.11 0.22
bIC (μU/mL) 19.31 13.54 3.13 0.28
bNEFA (μmol/L) 164.80 176.00 62.26 0.82
ssGC (mmol/L) 4.10 4.26 0.12 0.38
ssIC (μU/mL) 1,143.19 1,217.06 58.98 0.11
ssGIR (μmol/kg per min) 31.57 31.96 1.80 0.86
ISI 0.028 0.026 0.00 0.26
QUICKI 0.318 0.339 0.01 0.20
rQUICKI 0.191 0.194 0.01 0.14
1Values are LSM ± pooled SEM, n = 5.
2bGC = basal plasma glucose concentration; bIC = basal plasma insulin concentration; bNEFA = basal plasma 
NEFA concentration; ssGC = mean plasma glucose concentration during the steady-state; ssIC = mean plasma 
insulin concentrations during the steady-state; ssGIR = mean glucose infusion rate during the steady-state; 
ISI = insulin sensitivity index; QUICKI = quantitative insulin sensitivity check index (Katz et al., 2000); and 
rQUICKI = revised QUICKI (Perseghin et al., 2001; Holtenius and Holtenius, 2007).
Table 4. Insulin sensitivity indices determined during hyperglycemic clamp studies before (wk −1) and in wk 
3 of quercetin supplementation1 
Item
Week
SEM P-value−1 3
bGC (mmol/L) 4.19 4.19 0.13 0.98
bIC (μU/mL) 16.44 11.53 2.73 0.21
bNEFA (μmol/L) 125.38 78.75 14.85 0.12
ssGC (mmol/L) 6.30 6.36 0.18 0.85
ssIC (μU/mL) 23.33 26.44 3.67 0.65
ssGIR (μmol/kg per minute) 19.78 21.91 1.63 0.49
IIabs (μU/mL) 6.89 14.92 4.21 0.16
IIrel 1.63 2.39 0.38 0.012
ISI 0.854 0.916 0.13 0.78
QUICKI 0.327 0.333 0.01 0.55
rQUICKI 0.195 0.208 0.00 0.06
1Values are LSM ± pooled SEM, n = 5.
2bGC = basal plasma glucose concentration; bIC = basal plasma insulin concentration; bNEFA = basal plasma 
NEFA concentration; ssGC = mean plasma glucose concentration during the steady-state; ssIC = mean plasma 
insulin concentrations during the steady-state; ssGIR = mean glucose infusion rate during the steady-state; 
IIabs = absolute increase of plasma insulin concentration; IIrel = relative increase of plasma insulin concentra-
tion; ISI = insulin sensitivity index; QUICKI = quantitative insulin sensitivity check index (Katz et al., 2000); 
and rQUICKI = revised QUICKI (Perseghin et al., 2001; Holtenius and Holtenius, 2007).
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et al., 2013). The lack of constantly elevated flavonol 
plasma levels throughout the day (due to the rapid 
intestinal and postabsorptive metabolism of quercetin 
in cows; Gohlke et al., 2013) could explain the absence 
of alterations of gene expression. However, it is unclear 
whether this explains the absence of a quercetin ef-
fect on antioxidant enzymes. In rat studies in which an 
increase of the activity of SOD, CAT, and GPx activity 
in response to comparable quercetin doses administered 
once or twice daily was observed, it was not demon-
strated that constantly increased plasma concentrations 
of flavonols throughout the day are necessary to achieve 
the biological effect (Molina et al., 2003; Mahesh and 
Menon, 2004). Second, a potential effect of quercetin on 
the mentioned enzymes in vivo seems to be influenced 
by the health status of the subject and, to a smaller de-
gree, by the cell type investigated. In most experiments 
in which positive effects of quercetin on antioxidative 
status were observed, the animals were stressed; for 
example, through pre-existing diseases, streptozotocin-
induced diabetes, or artificially generated liver injuries 
(Molina et al., 2003; Sancheti et al., 2011; Jeong et 
al., 2012). In contrast, in healthy, nonstressed rats, an 
effect of quercetin on the activity of hepatic SOD and 
CAT could also not be demonstrated (Igarashi and 
Ohmuma, 1995). Third, we did not investigate other 
indices of the antioxidative status, such as plasma thio-
barbituric acid reactive substances as an indicator of 
lipid peroxidation, which might as well be altered in 
quercetin supplementation.
It should be noted that this study had limitations 
because of the small sample size. In addition, cows were 
used as their own controls and quercetin effects were 
related to a single point in time before quercetin ad-
ministration, and thus effects could be also partly due 
to stage of lactation. Presumably, the lack of perma-
nent elevation of flavonols in plasma might also play a 
role in this context. Therefore, in future studies, higher 
doses of quercetin administered more frequently should 
be used, together with a control group.
Table 5. Endogenous glucose production, plasma glucose rate of appearance during euglycemic hyperinsulinemic 
clamp studies and glucose oxidation before (wk −1) and in wk 3 of quercetin supplementation1 
Item2  
(mmol/kg per hour)
Week
SEM
P-value3
−1 3 Flav Clamp
Flav  
× Clamp
eGP 1.22 1.13 0.13 0.55 <0.01 0.83
GlucRaEHC 2.05 1.99 0.13 0.55 <0.01 0.83
cGlucRaEHC 0.152 0.117 0.05 0.43 — —
GOxBasal 0.348 0.319 0.06 0.74 <0.01 0.88
GOxEHC 1.429 1.421 0.06 0.74 <0.01 0.88
1Values are LSM ± pooled SEM, n = 5.
2eGP = endogenous glucose production calculated as mean glucose rate of appearance (GlucRa) between −90 
and 0 min relative to clamp start; GlucRaEHC = mean GlucRa calculated between 180 and 360 min relative to 
clamp start; cGlucRaEHC = GlucRaEHC corrected for the infusion of unlabeled glucose; GOxBasal = mean glucose 
oxidation rate calculated between −60 and 0 min relative to clamp start; and GOxEHC = mean glucose oxida-
tion rate calculated between 210 and 360 min relative to clamp start.
3Flav = flavonoid supplementation (yes or no); Clamp = before or during clamp study.
Table 6. Relative mRNA expression (E−ΔΔCq, where E = efficiency and Cq is quantification cycle) of hepatic 
genes before (wk −2), after 1 wk, and in 4 wk of quercetin supplementation1 
Gene2
Week
SEM P-value−2 1 4
G6P 22.988 17.672 18.657 2.72 0.36
PC 0.469 0.411 0.339 0.07 0.50
PEPCK-C 1.973 2.002 1.408 0.37 0.41
PEPCK-M 0.300 0.245 0.216 0.03 0.26
SOD 4.725 3.604 3.165 0.58 0.31
GPx 1.973 1.774 1.771 0.17 0.67
CAT 2.284 1.705 1.722 0.24 0.17
CPT1A 0.234 0.226 0.212 0.02 0.83
1Values are LSM ± pooled SEM, n = 4.
2G6P = glucose-6-phosphatase; PC = pyruvate carboxylase; PEPCK-C = cytosolic phosphoenolpyruvate car-
boxykinase; PEPCK-M = mitochondrial phosphoenolpyruvate carboxykinase; SOD = superoxide dismutase; 
GPx = glutathione peroxidase; CAT = catalase; CPT1A = carnitine palmitoyltransferase 1A.
Journal of Dairy Science Vol. 96 No. 11, 2013
CHRONIC QUERCETIN SUPPLEMENTATION IN DAIRY COWS 6997
CONCLUSIONS
A 4-wk duodenal supplementation of quercetin in 
cows at a dose of 36 mg/kg of BW per day resulted in 
slight but significant and conclusive changes in glucose 
metabolism, indicating increased insulin release and 
insulin sensitivity. The intraduodenal administration of 
approximately 21 g of QE per day and cow for a total 
period of 28 d did not affect production parameters, 
except for increased milk protein concentration. This 
suggests that quercetin might assist in the adaptation 
of high-yielding cows to lactation.
Figure 5. Liver glycogen (black bars) and fat (gray bars) content 
before quercetin administration (1), after 1 wk (2), and after 4 wk 
(3) of quercetin supplementation. Values are LSM ± SEM of 5 cows. 
Different symbols represent individual cows. For details of timing, see 
Figure 1. 
Table 7. Zootechnical data and milk composition before and during quercetin supplementation1 
Item
Week
SEM
P-value
−2 1 2 4 Week
BW (kg) 686.6ab 675.0b 679.4b 693.6a 7.56 <0.01
Circumference of abdomen (cm) 256.0 253.4 254.8 256.6 2.64 0.21
Circumference of breast (cm) 207.8 209.0 209.8 209.6 3.21 0.12
Back fat thickness (cm) 1.14 1.28 1.24 1.37 0.27 0.33
DMI (kg) 23.8 23.0 23.1 23.9 0.76 0.20
Milk yield (kg) 30.7ab 31.3ab 32.7a 28.7b 2.99 0.03
ECM (kg) 31.6 32.5 33.2 29.8 3.60 0.17
Milk fat content (%) 4.19 4.15 3.97 4.17 0.21 0.70
Milk lactose content (%) 4.81 4.75 4.81 4.78 0.06 0.55
Milk protein content (%) 3.37b 3.50ab 3.54a 3.54a 0.10 0.016
a,bMeans within a row with different superscript letters differ at P < 0.05.
1Values are LSM ± pooled SEM, n = 5. Wk +1 to + 4 denote values measured during quercetin supplementa-
tion. Data from wk −1 and 3 were excluded in the statistical evaluation because execution of clamp studies 
had a significant effect on some of the measured variables.
Figure 6. Plasma concentrations of BHBA before (210 DIM) and 
during quercetin (215–240 DIM) administration at 1200 h. Values are 
LSM ± SEM of 5 cows. Different symbols represent values of indi-
vidual cows. *Significantly different from baseline value (P ≤ 0.05). 
CLAMP area indicates days on which clamp studies were performed in 
the cows. For details of timing, see Materials and Methods. 
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